ALLERGIC RHINITIS TREATMENT MARKET ANALYSIS

Allergic Rhinitis Treatment Market, By Treatment Type (Immunotherapy (Sub-cutaneous Immunotherapy, Sub-lingual Immunotherapy), Anti-histamines, Decongestants, Leukotriene Receptor Antagonists, Corticosteroids, and Others), By Route of Administration (Oral, Nasal, Intraocular, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-commerce), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Feb 2025
Code : CMI1201
Pages :181
Formats :
Excel and PDF
Industry : Pharmaceutical

Allergic Rhinitis Treatment Market Size and Trends

The global allergic rhinitis treatment market is estimated to be valued at USD 16.91 Bn in 2025 and is expected to reach USD 23.81 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 5.0% from 2025 to 2032.

Allergic Rhinitis Treatment Market Key Factors

To learn more about this report, Request sample copy

The growing pollution levels across major cities due to rapid urbanization and industrialization have led to increased instances of allergies and other diseases. Furthermore, the rising patient awareness regarding the availability of various treatment options for allergic rhinitis is also contributing to the market growth. However, the presence of alternative treatment options and expiry of patents of blockbuster drugs may hamper the market growth. Overall, increasing environmental pollution and growing health consciousness among consumers are expected to drive the global allergic rhinitis treatment market growth during the forecast period.

Increasing Availability of Allergen Immunotherapy Solutions

The increasing availability of allergen immunotherapy solutions is one of the factors that is expected to drive the market growth during the forecast period. For instance, in June 2021, Stallergenes Greer, one of the global leaders in allergy immunotherapy, announced that the Alusta, subcutaneous allergen immunotherapy (SCIT) solution for different allergies involving rhinitis, conjunctivitis, rhino conjunctivitis, or asthma is now available in Spain and Italy.